M&As this week: Henry Schein, Leap Therapeutics, Eckert & Ziegler BEBIG

1 September 2016 (Last Updated September 1st, 2016 18:30)

Henry Schein, a healthcare products and services provider based in Poland, is set to acquire an 80% stake in Marrodent Spzoo, a dental distributor also based in Poland.

Henry Schein, a healthcare products and services provider based in Poland, is set to acquire an 80% stake in Marrodent Spzoo, a dental distributor also based in Poland.

The definitive agreement, which is awaiting approval from Poland's authorities, will enable the acquirer to expand its presence in the country by deploying the target company’s practitioners.

The transaction is expected to complete in Q4 2016.

Leap Therapeutics, an immuno-oncology company, has signed a definitive agreement to acquire biopharmaceutical firm, Macrocure, which will become a wholly-owned subsidiary of the acquirer, which in turn will become a public company upon completion of the transaction.

"The acquisition will help the two companies to advance two first-in-class immuno-oncology monoclonal antibodies targeting aggressive cancers."

The acquisition will help the two companies to advance two first-in-class immuno-oncology monoclonal antibodies targeting aggressive cancers.

A global provider of radiotherapy products, Eckert & Ziegler BEBIG has completed the acquisition of BrachySolutions BVBA, one of Europe's biggest independent distributors of prostate grains.

The acquisition results in Eckert & Ziegler gaining the latter’s customer base in Great Britain and Portugal, thereby strengthening its position in the European prostate grains market.